Actor portrayal
Platform
Three capabilities. One system.
Cerenome’s platform is one integrated system for central nervous system (CNS) cancers. It unites three capabilities: precision diagnostics, targeted radiotherapeutics, and data insights, so that detecting, treating, and learning from these cancers happen as one connected process.
Why One System
One connected process.
Cancers of the brain and spinal cord are hard to detect, hard to reach, hard to study, and hard to manage. For decades they were approached in fragments—detection, treatment, and data as separate businesses, handing off the rest and losing detail along the way. Progress stalled.
We built a system to combat that. A diagnosis shapes the treatment. The treatment’s response becomes data. That data refines the approach to future patients, so each one starts from a better place than the last.
Diagnostics
Identify and characterize disease
Therapeutics
Target and treat disease
Data Insights
Turn data into actionable intelligence
Diagnostics
How the system sees.
Reads the disease in the cerebrospinal fluid through commercially available CNSide®, producing the cellular and molecular profiles that patient and treatment selection and targeting depend on. Every result feeds the data layer.
Therapeutics
How the system takes action.
Treats against that profile with investigational REYOBIQ™, reaching tumors the blood-brain barrier keeps most drugs away from. Every response feeds the data layer.
Data Insights
How the system remembers.
The layer that makes the other two better. It holds every cerebrospinal fluid (CSF) result alongside every treatment response, so diagnostics learn from treatment and treatment learns from diagnostics.
Inside the thinking.
Hear from Colby Suire, PhD, Vice President of Research & Development, on why Cerenome views diagnostics, therapeutics, and data as one system, and what that changes about how CNS cancers are approached.
The platform, in practice.
Leptomeningeal metastases show the system working most clearly. The cancer lives in the cerebrospinal fluid (CSF) and meninges, a space standard tools struggle to access and interpret. Cerenome works there directly: CNSide® brings cellular and molecular visibility to the CSF, and REYOBIQ™ is designed to deliver treatment into that same space.
So diagnosis and treatment meet on the same disease in the same place, and what happens next is recorded rather than lost.